Groupe d'Etude en Oncologie du Quebec

Titre	A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma
Protocole ID	TAC01-CD19-01
ClinicalTrials.gov ID	NCT03880279
Type(s) de cancer	Lymphome non-hodgkinien (LNH)
Phase	Phase I-II
Stade	Maladie réfractaire
Type étude	Traitement
Médicament	Technologie TAC - TAC01-CD19
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	Montréal
Investigateur(trice) principal(e)	Dre Isabelle Fleury
Coordonnateur(trice)	Michel-Olivier Gratton 514-252-3400 poste 2397
Statut	Actif en recrutement
Critètes d'éligibilité	Histologically confirmed CD19+ Large B-Cell Lymphoma including Diffuse Large B-cell Lymphoma (DLBCL) not otherwise specified (including de novo and transformed lymphoma), Primary Mediastinal Large B-cell Lymphoma, High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangement per WHO 2016 classification. Relapsed or refractory disease after greater than 2 lines of therapy including anthracycline and anti-CD20 therapy and either having failed autologous stem cell transplant (ASCT) or being ineligible for ASCT. ECOG 0-1. Adequate organ function.
Critètes d'exclusion	Prior treatment with any of the following: allogeneic bone marrow transplantation, gene therapy, adoptive cell transfer of any kind, including CAR T cells. Active central nervous system (CNS) lymphoma involvement. History or presence of clinically relevant CNS pathology. Active inflammatory neurological disorders, autoimmune disease, or infections.

Groupe d'étude en oncologie du Québec